Inozyme Pharma (INZY) to Release Earnings on Tuesday

Inozyme Pharma (NASDAQ:INZY) is expected to announce its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter.

Inozyme Pharma Trading Down 9.2 %

NASDAQ:INZY opened at $1.09 on Tuesday. The company has a market cap of $70.02 million, a P/E ratio of -0.70 and a beta of 1.29. The stock’s fifty day moving average price is $1.80 and its two-hundred day moving average price is $3.49. Inozyme Pharma has a 1 year low of $1.09 and a 1 year high of $7.80. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on INZY shares. Piper Sandler dropped their target price on Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, January 13th. Wedbush restated an “outperform” rating and set a $12.00 target price on shares of Inozyme Pharma in a research report on Friday, January 10th. Wells Fargo & Company dropped their target price on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, January 13th. Raymond James started coverage on Inozyme Pharma in a research report on Thursday, December 12th. They set an “outperform” rating and a $26.00 target price on the stock. Finally, HC Wainwright increased their price objective on Inozyme Pharma from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $18.33.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.